Verinurad
A highly potent and specific URAT1 inhibitor with IC50 of 25 nM; displays 200-fold lower affinity for the related URAT1 homologs OAT4 and OAT1; reduces the sUA by up to 60% with a single 40 mg dose in healthy human volunteers, and increases the FEUA in a dose-dependent manner with EC50 of 22 nM; currently in phase 2 trials for the treatment of gout and asymptomatic hyperuricemia.Gout Phase 2 Clinical (In Vitro) :Verinurad inhibits the transport activity of human URAT1 in a dose-dependent manner, at high potency with an IC50 of 25 nM.
Product Specifications
CAS Number
1352792-74-5
Product Name Alternative
RDEA-3170
Purity
>98% (HPLC)
Solubility
10 mM in DMSO
Smiles
CC (C) (SC1=C (C2=C3C=CC=CC3=C (C#N) C=C2) C=NC=C1) C (O) =O
Molecular Formula
C20H16N2O2S
Molecular Weight
348.4182
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Propanoic acid, 2-[[3- (4-cyano-1-naphthalenyl) -4-pyridinyl]thio]-2-methyl-
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
A6200-SC Printer Applicator Accessories
HRP-Linked Polyclonal Antibody to B-Cell Activation Factor Receptor (BAFFR)
HRP-Linked Polyclonal Antibody to B-Cell Activation Factor Receptor (BAFFR)